BRIEF published on 09/09/2024 at 22:40, 2 years ago ABIVAX presents its 2024 half-year results Cybersecurity Abivax Half-year Results Internal Control Failures
BRIEF published on 09/09/2024 at 22:06, 2 years ago Abivax financial results for the first half of 2024 Financial Results Biotechnology Abivax First Half Of 2024 Immune Mechanisms
PRESS RELEASE published on 09/09/2024 at 22:01, 2 years ago Abivax presents first-half 2024 financial results Abivax presents first-half 2024 financial results with a cash balance of EUR 222M at June 30, 2024. The company focuses on developing therapies for chronic inflammatory diseases Financial Results Abivax Therapeutics Chronic Inflammatory Diseases EUR 222M
BRIEF published on 08/29/2024 at 18:05, 2 years ago ABIVAX: Status of shares and voting rights as of July 31, 2024 Euronext Paris Voting Rights Actions Abivax Regulatory
BRIEF published on 08/06/2024 at 08:35, 2 years 1 month ago Abivax Reaches Key Milestone with Recruitment of 600 Patients for Phase 3 ABTECT Trial Patient Recruitment Abivax Obefazimod Ulcerative Colitis Clinical Test
PRESS RELEASE published on 08/06/2024 at 08:30, 2 years 1 month ago Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Abivax announces ABTECT Phase 3 Trial surpasses 600-patient enrollment milestone, on track for full enrollment by early Q1 2025. Trial trends align with previous observations Abivax Obefazimod Ulcerative Colitis ABTECT Phase 3 Trial Enrollment Milestone
BRIEF published on 07/23/2024 at 18:05, 2 years 1 month ago ABIVAX: Number of shares and voting rights as of June 30, 2024 Voting Rights Euronext Actions AMF Abivax
BRIEF published on 07/23/2024 at 18:05, 2 years 1 month ago ABIVAX: Half-yearly review of the liquidity contract as of June 30, 2024 Liquidity Contract Actions Financial Transactions Abivax First Half Of 2024
BRIEF published on 07/22/2024 at 09:51, 2 years 1 month ago Threshold crossing by Deep Track Biotechnology Master Fund Voting Rights Abivax Crossing Threshold Off-market Acquisition Deep Track Biotechnology
BRIEF published on 07/15/2024 at 22:05, 2 years 2 months ago Abivax announces advances in its clinical program and updates its operations Treasury Ulcerative Colitis Nomination Update Clinical Program
Published on 09/16/2026 at 23:45, 8 hours 30 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 10 hours 45 minutes ago Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 15 hours 20 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 17 hours 15 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 18 hours 15 minutes ago Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/17/2026 at 08:05, 9 minutes ago CookieYes Launches MCP Server to Manage Cookie Consent Inside Claude and ChatGPT
Published on 09/17/2026 at 07:15, 1 hour ago Infracore ergänzt ihr Angebot für die Immobilien des Spitals Wetzikon und verlängert dessen Gültigkeit bis zum 31. Oktober 2026
Published on 09/17/2026 at 07:00, 1 hour 14 minutes ago Helvetia Baloise delivers strong half-year operating results and fast integration progress while maintaining excellent capitalisation
Published on 09/17/2026 at 07:00, 1 hour 15 minutes ago MCH Group continues its progress with a strong first half year result, further strengthening profitability
Published on 09/16/2026 at 17:45, 14 hours 30 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 1 hour ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 14 hours ago Report on the Combined General Meeting of the 10th of September 2026
